



Practitioner's Docket No. U 014821-4

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application

of \_\_\_\_\_

Inventor(s)

for \_\_\_\_\_

Title of invention

OR

In re application of: Vie Yang CHEN, et al

Serial No.: 10/669,836

Group No.: \_\_\_\_\_

Filed: September 24, 2003

Examiner.: \_\_\_\_\_

For: IN VITRO ASSAY FOR EVALUATION OF ANGIOGENIC EFFECTS

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF FILING OR  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\*

(When using Express Mail, the Express Mail label number is **mandatory**;  
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

37 C.F.R. 1.10\*

- ☒ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_ (mandatory)

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: November 24, 2003

Signature

CLIFFORD J. MASS

(type or print name of person certifying)

\* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

NOTE: 37 C.F.R. 1.98(b):

- (1) *Each U.S. patent listed in an information disclosure statement must be identified by inventor, patent number, and issue date.*
- (2) *Each U.S. patent application published listed in an information disclosure statement shall be identified by applicant, patent application publication number, and publication date.*
- (3) *Each U.S. application listed in an information disclosure statement must be identified by the inventor, application number, and filing date.*
- (4) *Each foreign patent or published foreign patent application listed in an information disclosure statement must be identified by the country or patent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application.*
- (5) *Each publication listed in an information disclosure statement must be identified by publisher, author (if any), title, relevant pages of the publication, date, and place of publication.*

**WARNING:** *No extension of time can be had under 37 C.F.R. § 1.36 (a) or (b) for filing an IDS. 37 C.F.R. § 1.97(f).*

NOTE: *The "filing date of a national application" under 37 C.F.R. 1.97(b) has two possible meanings. Where the filing is a direct one to the United States Patent & Trademark office, the filing is defined in 37 C.F.R. 1.53(b) as "the date on which: (1) A specification containing a description pursuant to § 1.71 and at least one claim pursuant to § 1.75; and (2) any drawing required by § 1.81(a), are filed in the Patent and Trademark Office in the name of the actual inventor or inventors as required by § 1.41." 37 C.F.R. 1.97(b)(1). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents and fees required by 35 U.S.C. § 371(c) within the periods set forth in § 1.494 or § 1.495. 35 U.S.C. § 371(c) requires the filing of the following: (1) the national fee; (2) a copy of the international application, unless already sent by the International Bureau, and an English translation if filed in another language; (3) amendments under PCT Article 19, with a translation into English if made in another language; (4) an oath or declaration; and (5) a translation into English of any annexes to the international preliminary examination report, if such annexes were made in another language. 37 C.F.R. 1.97(b)(2).*

### **IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. 1.97(b).

NOTE: *"No certification or fee is due when the filing is made within the above time period. It is advisable to ensure that no Office action has been mailed if the disclosure statement is delayed until after three months from filing."*

NOTE: *"An information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a mailing if accompanied by a properly executed certificate of mailing under 37 C.F.R. 1.8, or Express Mail certificate under 37 C.F.R. 1.10. An office action is mailed on the date indicated in the Office action." Notice of April 20, 1992 (1138 O.G. 37-41, 39).*

NOTE: *"The term 'national application' includes continuing applications (continuations, divisions, continuations-in-part) so three-months will be measured from the actual filing date of an application as opposed [sic] to the effective date of a continuing application." Notice of April 20, 1992 (1138 O.G. 37-41, 39).*

**NOTE:** "An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirements (37 C.F.R. 1.142) or just a requirement for additional fees to have a claim considered (37 C.F.R. 1.16(d)). Thus, if an application was filed on Jan. 1 and the first Office action on the merits was not mailed until six months later on July 1, the examiner would be required to consider any proper information disclosure statement filed prior to July 1." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

**WARNING:** "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 63).

Reg. No. 30,086

Tel. No.: (212) 708-1890

Customer No.: 00140



SIGNATURE OF PRACTITIONER

CLIFFORD J. MASS

(type or print name of practitioner)

P.O. Address

c/o Ladas & Parry  
26 West 61<sup>st</sup> Street  
New York, N.Y. 10023



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Vie Yang CHEN, et al  
Serial No.: 10/669,836                      Group No.:  
Filed: September 24, 2003                      Examiner.:  
For: IN VITRO ASSAY FOR EVALUATION OF ANGIOGENIC EFFECTS

Attorney Docket No.: U 014821-4

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the attached references which are considered in the specification and which are also listed on the attached Form PTO-1449.

**CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\***

*(When using Express Mail, the Express Mail label number is mandatory;  
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. 1.8(a)**

**37 C.F.R. 1.10\***

- ☒ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Address"  
Mailing Label No. \_\_\_\_\_ (mandatory)

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: November 24, 2003


Signature

CLIFFORD J. MASS

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).  
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Respectfully submitted,



CLIFFORD J. MASS  
LADAS & PARRY  
26 WEST 61ST STREET  
NEW YORK, NEW YORK 10023  
REG. NO.30,086(212)708-1890

FORM PTO-1449

U. S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO.

U 014821-4

10/669,836

APPLICANT

Via YANG CHENG, et al.

FILING DATE

GROUP

09/24/2003

## OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

AA	Wang, De-Yang. "Mechanistic Studies of the Endothelial Cell Morphogenesis <i>In Vitro</i> ." Master's Thesis, Abstract. Department of Biology, TungHai University, Taiwan. 1993.
AB	Folkman, Judah. "What is the Role of Endothelial Cells in Angiogenesis?" <i>Laboratory Investigation</i> , 1984, 51(6), pp. 601-604.
AC	Jain, R. K. And P. F. Carmeliet. "Vessels of Death or Life." <i>Scientific American</i> , Dec. 2001, pp. 38-45.
AD	Cross, M. J. and Lena Claesson-Welsh. "FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition." <i>Trends in Pharmacological Sciences</i> , Apr. 2001, 22(4), pp. 201-207.
AE	Iwasaka, C., et al. "Ets-1 Regulates Angiogenesis by Inducing the Expression of Urokinase-Type Plasminogen Activator and the Matrix Metalloproteinase-1 and the Migration of Vascular Endothelial Cells." <i>J. Cellular Physiology</i> , 1996, 169, pp. 522-531.
AF	Nakano, Toru et al. "Angiogenesis Inhibition by Transdominant Mutant Ets-1." <i>J. Cellular Physiology</i> , 2000, 184, pp. 255-262
AG	Kondo, Takako et al. "Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding." <i>Cancer Letters</i> , 2002, 180, pp. 200-262.
AH	Chen, Zong Ping et al. "Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts." <i>Cancer Letters</i> , 1998, 129, pp. 173-179.
AI	Combe, Bernard. "Thalidomide: new indications?" <i>Joint Bone Spine</i> , 2001, 68, pp. 582-587.
AJ	Dameron, K.M., et al. "Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin -1." <i>Science</i> (1994) 265, pp 1582-1584
AK	Chen, Jan-Kan et al. "Inhibition of the growth of a human nasopharyngeal carcinoma cell line by bFGF is mediated via FGFR-1." <i>FASEB J.</i> , Sept. 1995, 9, pp. 1211-1219.
AL	Stephens, T. D. et al. "Mechanism of Action in Thalidomide Teratogenesis." <i>Biochem. Pharmacology</i> , 2000, 59, pp. 1489-1499.
AM	Hagedorn, Martin and Andreas Bikfalvi. "Target molecules for anti-angiogenic therapy: from basic research to clinical trials." <i>Critical Reviews in Oncology/Hematology</i> , 2000, 34, pp. 89-110.
AN	Diglio, C. A. et al. "Angiogenesis in Rat Aorta Ring Explant Cultures." <i>Laboratory Investigation</i> , 1989, 60(40), pp. 523-531.
AO	Scott, K. A. et al. "A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction." <i>FEBS Letters</i> , 1998, 441, pp. 137-140.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U. S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

U 014821-4

10/669,836

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Via YANG CHENG, et al.

FILING DATE

GROUP

09/24/2003

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

AA	Sharma, S. et al. "A Quantitative Angiogenesis Model for Efficacy Testing of Chemopreventive Agents." <i>Anticancer Research</i> , 20001, 21, pp. 3829-3838.
AB	Kuo, Shih-Wei et al. "The <i>in vitro</i> Model of Angiogenesis and Its Application." English Abstract and three Chinese-language sheets. Eleventh Symposium on Recent Advances in Cellular and Molecular Biology.
AC	BD BioCoat Angiogenesis System for Endothelial Cell Invasion. Marketing Information Sheets and Product Specification Sheets (7/13/01, p. 1-2). BD Biosciences Discovery Labware.
AD	
AE	
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	
AO	

EXAMINER

DATE CONSIDERED

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.